
WALD Stock Forecast & Price Target
WALD Analyst Ratings
Bulls say
Waldencast is facing some challenges in the short term due to missed revenue expectations, margin pressure and a lack of guidance for FY26. However, the company's recent sale of Obagi Japan trademarks and improvements to the balance sheet through debt repayment demonstrate a commitment to improving financials. In the long term, the entry of Obagi into the filler market and momentum in their eCommerce channels show potential for increased growth. Risks to the investment include volatility in commodity costs, access to capital, and geopolitical uncertainty in the beauty and wellness industry.
Bears say
Waldencast is facing a negative outlook due to its ongoing strategic review, reliance on third-party suppliers and distributors, potential dilution from future securities, and concentration of share ownership among SPAC sponsors. Additionally, slowdown in the beauty market, ongoing SEC investigation, and potential inflation and supply chain pressures could add further strain on the company's financials. These factors raise concerns about the long-term sustainability and growth potential of Waldencast, leading to a negative outlook.
This aggregate rating is based on analysts' research of Waldencast Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
WALD Analyst Forecast & Price Prediction
Start investing in WALD
Order type
Buy in
Order amount
Est. shares
0 shares